Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-09-09 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
2023年股权激励计划首次授予部分第一个行权期股票期权行权结果公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the results of the first exercise period of a 2023 stock option incentive plan by Beijing Xinghao Pharmaceutical Co., Ltd. It includes specifics such as the number of options exercised, the exercise price, the number of participants, changes in shareholding before and after exercise, and the impact on the company's financials. It also references a capital verification report and the use of funds raised. The document is not a full financial report like an Annual or Interim Report, nor is it a simple announcement of a report publication. It is a specific update on capital/financing activity related to stock option exercises, which fits the Capital/Financing Update (CAP) category.
2025-09-09 Chinese
申万宏源证券承销保荐有限责任公司关于北京星昊医药股份有限公司2025年半年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a '2025 Half-Year Continuous Supervision Follow-up Report' issued by a securities underwriting and sponsorship company regarding Beijing Xinghao Pharmaceutical Co., Ltd. It details ongoing supervision activities, including review of company disclosures, financial data, shareholder registers, internal controls, and fundraising usage. The document is a follow-up report on the company's half-year period, focusing on compliance, supervision, and internal controls rather than presenting comprehensive financial statements or earnings results. It is not an annual or interim financial report but a regulatory supervision report related to the half-year period. Given the nature of the document as a continuous supervision follow-up report issued by the sponsor, it aligns best with the category of Audit Report / Information (AR), which includes standalone audit or regulatory supervision reports excluding full annual or interim reports. The document length is 2088 characters, which is short but contains substantive supervisory content rather than just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is AR with high confidence. H1 2025
2025-08-20 Chinese
关于公司撤回药品注册申请的进展公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the withdrawal of a drug registration application. It includes details about the drug, the regulatory approval to withdraw the application, the impact on the company, and risk warnings. The document is short (1004 characters) and serves as a regulatory announcement about a specific event related to the company's drug registration process. It does not contain financial statements, audit information, or detailed management discussion. It is not a report or presentation but a formal announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-08-12 Chinese
第七届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's seventh board of directors' third meeting. It details the meeting's attendance, agenda items, and voting results. The document references other reports (such as the 2025 semi-annual report and a special report on fundraising usage) that are disclosed elsewhere, but this document itself does not contain the full reports or detailed financial data. It is primarily a board meeting resolution announcement, not the actual financial or interim report. Given the content and length (1465 characters), it fits best as a Board/Management Information (MANG) filing, which covers announcements of board decisions and management matters.
2025-08-07 Chinese
申万宏源证券承销保荐有限责任公司关于北京星昊医药股份有限公司对外担保的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a securities underwriting and sponsorship company regarding an external guarantee provided by Beijing Xinghao Pharmaceutical Co., Ltd. It includes specific financial data, guarantee amounts, terms, and compliance with regulatory requirements. The content focuses on the external guarantee and related financial and legal compliance, not on a full annual or interim financial report, earnings release, or management discussion. It is a specialized report related to audit and regulatory compliance of a specific financial guarantee matter. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is 2077 characters, which is too long for a simple announcement and contains substantive content, so it is not a report publication announcement or regulatory filing. Hence, the classification is AR with high confidence. H1 2025
2025-08-07 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" or "Interim Report Summary" for the year 2025. It contains detailed financial data such as total assets, net profit, earnings per share, and other financial metrics for the half-year period. It also includes business descriptions, shareholder information, and notes on asset restrictions. The document length is 6736 characters, which is sufficient to contain substantive financial data and analysis. The content is consistent with an Interim / Quarterly Report, providing comprehensive financial and operational information for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or a certification, and it is not a full annual report (10-K). Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2025
2025-08-07 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.